Dallas, TX -- (ReleaseWire) -- 11/21/2012 -- The Drug Delivery Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 2,000 links to online copies of actual drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of drug delivery dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading drug delivery deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of drug delivery deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in drug delivery partnering and dealmaking since 2007.
In addition, a comprehensive appendix is provided organized by drug delivery partnering company A-Z, deal type definitions and drug delivery partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of drug delivery technologies and products.
Drug Delivery Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to drug delivery trends and structure of deals entered into by leading companies worldwide.
This research includes:
- Trends in drug delivery dealmaking in the biopharma industry since 2007
- Analysis of drug delivery deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life drug delivery deals
- Access to over 2,000 drug delivery contract documents
- The leading drug delivery deals by value since 2007
- Most active drug delivery dealmakers since 2007
- The leading drug delivery partnering resources
In Drug Delivery Partnering Terms and Agreements, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key Benefits of this report:
- In-depth understanding of drug delivery deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of drug delivery agreements with numerous real life case studies
- Comprehensive access to over 2,000 actual drug delivery contracts entered into by the world’s biopharma companies
- Detailed access to actual drug delivery contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a drug delivery agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Buy your copy of this report @ http://www.reportsnreports.com/reports/206436-drug-delivery-partnering-terms-and-agreements.html .Contact email@example.com for further information.
Bigpharma Drug Delivery Partnering Company Profiles
6. Aspen Pharmacare
9. Baxter International
11. Biogen Idec
12. Boehringer Ingelheim
13. Bristol-Myers Squibb
16. Daiichi Sankyo
17. Dainippon Sumitomo
19. Eli Lilly
20. Endo Pharmaceuticals
21. Forest Laboratories
23. Gilead Sciences
27. Johnson & Johnson
28. Kyowa Hakko Kirin
31. Merck & Co
32. Merck KGaA
33. Mitsubishi Tanabe
35. Novo Nordisk
46. Warner Chilcott